Good
Start Genetics®, Inc., an innovative molecular
diagnostics company harnessing a powerful, proprietary next-generation
DNA sequencing (NGS) capability, today announced that Don Hardison,
president and chief executive officer, is scheduled to present an
overview of the company at the 32nd Annual J.P. Morgan
Healthcare Conference on Tuesday, January 14 at 7:30 a.m. PT. The
conference is being held January 13-16, 2014 at the Westin St. Francis
Hotel in San Francisco.
About GoodStart Select™
GoodStart Select is Good Start Genetics’ menu of carrier
screening tests that, for diseases such as cystic fibrosis, detects many
more disease-causing mutations than any other routine carrier screening
test, regardless of patient ethnicity. After years of development and
rigorous validation, Good Start Genetics has harnessed the power of its
sophisticated technologies, including next-generation DNA sequencing
(NGS), to provide highly accurate and actionable tests resulting in
higher mutation detection rates and fewer missed carriers. Good Start
offers genetic screening tests for all disorders recommended by the
American Congress of Obstetricians and Gynecologists (ACOG), the
American College of Medical Genetics and Genomics (ACMG), and leading
Jewish advocacy groups.
To support the company’s genetic screening capabilities, Good Start has
a dedicated team of customer care specialists, board certified medical
geneticists and genetic counselors who provide step-by-step support,
from test selection through results, analysis and reporting. For these
reasons, reproductive health specialists and their patients can have the
highest degree of confidence in their genetic carrier screening results.
About
Good Start Genetics, Inc.
Good Start Genetics is an innovative molecular diagnostics company
harnessing a powerful, proprietary next-generation DNA sequencing (NGS)
capability combined with other technologies to deliver superior tests
for routine genetic screening. Through its GoodStart Select
offering, the company provides the most comprehensive and clinically
actionable set of tests for known and novel mutations that cause
inherited diseases. Good Start’s NGS capabilities can be applied to
multiple disease areas, including pre-conception carrier screening in
the in-vitro fertilization setting. For more information, please
visit www.goodstartgenetics.com.
Copyright Business Wire 2014